PODD Stock Insulet Corporation
US · NasdaqGSLast in our picks 2026-10-24 — not in the current list; analysis below is from that screen
Tubeless insulin delivery growth offers strong recurring-revenue expansion and operating leverage.
Future value: $167.17 (+12.19%) · 6-12 months · analyst consensus
Signal breakdown
- ▸High sales-growth outlook and majority-buy analyst coverage.
- ▸Above 50-day MA (+6.06%)
- ▾Near 52-week low (9.9% of range)
Is PODD a buy right now?
Trend: PODD is trading above the 50-day average (+6.14%), RSI 45 — neutral momentum, with a 3-month return of -10.87%.
Valuation & quality: Insulet Corporation trades on a trailing P/E of 28.0, forward P/E 19.3, PEG 1.17, price-to-book 7.28; fundamentals show net margin 12.3%, return on equity 26.0%, revenue growth 23.5% year on year.
Analyst consensus: 23 analysts have a mean 12-month price target of $167.17 (+12% vs the last close; range $143.00 – $215.00), consensus rating “buy”.
Our screen: BUY (score 3) — Tubeless insulin delivery growth offers strong recurring-revenue expansion and operating leverage.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -14.90% | -18.00% | -15.80% | +5.00% | +8.60% | -10.10% | -12.20% | +14.40% |
Fundamentals
Analyst price target
Technical signals
About Insulet Corporation
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally.
Sector: Healthcare · Industry: Medical Devices · United States · 5,400 employees · Website
Related Health Care picks
Browse: all US stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.